Keyphrases
Human Papillomavirus Vaccine
100%
Hazard Ratio
100%
Confidence Interval
83%
Birth Cohort
83%
Atypia
66%
Cervical Lesions
66%
Cervical Intraepithelial Neoplasia Grade 3
50%
Cervical Intraepithelial Neoplasia Grade 2
50%
Vaccination Status
33%
Risk Reduction
33%
Denmark
33%
Quadrivalent Human Papillomavirus Vaccine
33%
Cox Proportional Hazards Model
16%
Population Level
16%
Pathology Data
16%
Vaccination Program
16%
HPV18
16%
Clinical Trials
16%
Nationwide Registry
16%
High-risk Human Papillomavirus (HR-HPV)
16%
Unvaccinated
16%
Incident Cases
16%
Licensure
16%
Cohort Design
16%
HPV16
16%
Highly Effective
16%
Medicine and Dentistry
Hazard Ratio
100%
Wart Virus
100%
Cervical Intraepithelial Neoplasia
50%
Wart Virus Vaccine
33%
Gene Linkage
16%
Human Papillomavirus Type 18
16%
Proportional Hazards Model
16%
Clinical Trial
16%
Human Papillomavirus Type 16
16%
Cohort Analysis
16%